Spero Therapeutics, Inc.
SPRO · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 48.58M | 48.58M | -42.20M | -46.42M | -1.23 |
| 2023 FY | 103.78M | 52.34M | 21.48M | 22.81M | 0.43 |
| 2024 FY | 47.98M | -48.78M | -73.36M | -68.57M | -1.27 |
| 2025 FY | 59.62M | 59.62M | -24.00K | 8.57M | 0.15 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 124.80M | 48.87M | 109.11M | 6.65M | 75.93M |
| 2023 FY | 182.39M | 75.50M | 76.33M | 5.54M | 106.89M |
| 2024 FY | 110.54M | 64.42M | 52.89M | 4.30M | 46.12M |
| 2025 FY | 68.92M | 9.90M | 40.27M | 2.90M | 59.02M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -7.73M | — | -7.73M | — | -3.48M |
| 2023 FY | -33.00M | — | -33.00M | — | -32.77M |
| 2024 FY | -23.44M | — | -23.44M | — | -23.44M |
| 2025 FY | -12.62M | — | -12.62M | — | -12.62M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 65.02M | -37.44M | — | — | — |
| 2023 FY | 77.47M | 6.68M | — | — | — |
| 2024 FY | 55.66M | 7.07M | — | — | — |
| 2025 FY | 130.53M | 93.16M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 11.80M | 11.80M | -2.44M | -1.70M | -0.03 |
| 2025 Q3 | 3.05M | 3.05M | -7.92M | -7.38M | -0.13 |
| 2025 Q4 | 39.66M | 39.66M | 31.41M | 31.52M | 0.56 |
| 2026 Q1 | 258.00K | 258.00K | -7.54M | -7.20M | -0.13 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 62.12M | 29.29M | 31.19M | 3.62M | 32.83M |
| 2025 Q3 | 54.17M | 27.68M | 48.62M | 3.35M | 26.49M |
| 2025 Q4 | 68.92M | 9.90M | 40.27M | 2.90M | 59.02M |
| 2026 Q1 | 59.02M | 6.09M | 56.13M | 2.47M | 52.93M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -17.69M | — | -17.69M | — | -17.69M |
| 2025 Q3 | 17.42M | — | 17.42M | — | 17.42M |
| 2025 Q4 | -8.35M | — | -8.35M | — | -8.35M |
| 2026 Q1 | 15.86M | — | 15.86M | — | 15.86M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 162.48M | 134.90M | — | — | — |
| 2025 Q3 | 105.81M | 60.54M | — | — | — |
| 2025 Q4 | 130.53M | 93.16M | — | — | — |
| 2026 Q1 | 134.04M | 80.38M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |